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Abstract:
Background: Gastrointestinal (GI) dysfunction is prevalent in Parkinson’s disease (PD).
Symptoms are evident throughout the disease course, affect the length of the GI tract and impact on
patient quality of life and management. We clarify real-life differences in the frequency and
severity of GI symptoms in a cohort of PD and healthy control (HC) subjects.

Methods: 103 PD patients were compared to 81 HC subjects. Outcome measures collected from
validated questionnaires included constipation severity, upper and lower GI symptoms and physical
activity.

Results: PD patients were three-times more likely to experience constipation than HC subjects,
(78.6% vs 28.4%), exhibited a fourfold increase in constipation severity and formed harder stools.
PD patients also reported increased symptoms of indigestion, nausea, excessive fullness and
bloating, compared to the HCs. A higher mean Leeds Dyspepsia Questionnaire score for PD
patients (8.3 (standard deviation (SD) 7.7) vs 4.6 (SD 6.1), p=0.001)) indicated increased symptom
severity. Chronic pain was more frequently reported and correlated with constipation and upper GI
dysfunction, being more prevalent and severe in women. Physical activity was notably decreased in
the PD cohort (1823.6 (± 1693.6) vs 2942.4 (± 2620.9) metabolic equivalent-minutes/week,
p=0.001) and correlated with constipation severity. PD therapies were associated with increased
fullness and bloating and harder stools.

Conclusions: PD patients report more prevalent and severe GI dysfunction, although our cohort
comprised of many later-stage participants. Earlier recognition of GI dysfunction in PD provides
the opportunity to direct treatment for chronic pain and constipation, promote physical activity and
rationalise PD therapies for optimal patient care.
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Introduction:
PD is an incurable multisystem disorder that contributes to significant morbidity and healthcare
burden [1]. GI dysfunctions are the most prevalent non-motor symptoms (NMS) of PD, being
present in approximately 65% of patients [2] and conferring a considerably negative impact on
quality of life (QoL) [3, 4]. Common GI symptoms include constipation, bloating, drooling,
dysphagia, nausea, vomiting and gastroparesis and can precede motor symptoms by up to 20 years
[5-7]. Symptoms are evident throughout the disease course and involve the whole length of the GI
tract [8].

Consistent with clinico-epidemiological observations, several neuropathological studies have found
early accumulation of Lewy bodies (LB) in the Enteric Nervous System (ENS) and dorsal motor
nucleus of the vagus. These findings correlate with motor and gastrointestinal symptom severity, [9,
10] and reflect impaired intestinal peristalsis / motility, vagal dysfunction, altered intestinal
permeability, sensory impairments of the GI tract as well as medication effects, which together can
influence GI dysfunction in PD [11, 12].

GI disorders, such as malnutrition, aspiration pneumonia, megacolon, intestinal obstruction and
intestinal perforation, are a frequent cause of hospitalisation in PD [1, 5, 13]. In addition,
approximately 40-50% of PD patients report suffering from chronic constipation, whereby the
frequency is dependent on the type of questionnaire used [14]. Constipation is believed to result
from delayed GI transit and paradoxical contraction of voluntary sphincters during defecation [15,
16]. Constipation severity has been suggested to predict a faster motor and cognitive disease
progression, as well as severely impacting QoL [17].

The treatment of GI dysfunction in PD is often ineffective and frequently complicated by sideeffects [12]. Gastroparesis and delayed intestinal absorption negatively impact on treatment,
causing erratic levodopa uptake that may lead to motor fluctuations [18]. Emerging research also
suggests that the bidirectional communication between the gut and the brain, termed the microbiotagut-brain-axis, may further impact GI dysfunction, PD pathogenicity, [19, 20] and levodopa
metabolism [21].
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Given the evident and considerable association between GI dysfunction and PD, this study
examined the patterns of GI dysfunction in an Australian PD cohort using self-reported symptoms
of upper and lower GI dysfunction, QoL and clinical features relating to patient management.

Methods:

Study settings and subjects
Subjects were consecutively recruited from the movement disorder and neurology clinics at Royal
North Shore Hospital, Sydney, Australia, between 2018 and 2019. Inclusion criteria were, 1) >18
years of age, 2) a clinical diagnosis of idiopathic PD according to the UK Parkinson's Disease
Society Brain Bank Diagnostic Criteria [22], and 3) being managed by a specialist neurologist. The
HC inclusion criteria were, 1) >18 years of age, 2) exhibiting no clinical indication of PD, and 3) a
spouse, sibling or child with similar dietary habits to their respective PD subject. Exclusion criteria
included secondary Parkinsonism, tube feeding, medical or surgical disorders preventing
completion of questionnaires and significant cognitive impairment demonstrated by incapacity to
provide consent. Ethical approval was granted by the Northern Sydney Local Health District
Human Research Ethics Committee and the North Shore Private Hospital ethics committee,
HREC/18/HAWKE/109, NSPHEC 2018-LNR-009 respectively. Written informed consent was
obtained from all patients at the time of recruitment.

Data collection
Patients completed self-administered questionnaires, as well as providing a stool and blood sample
at the time of recruitment. Stool samples were assessed according to the Bristol Stool Scale (BSS)
[23], whilst blood samples were assessed for liver function tests, glycaemic profiles, non-fasting
lipid profiles, Erythrocyte Sedimentation Rate and C-Reactive Protein.

Information regarding socio-demographic factors, lifestyle and clinical management was collected
from validated surveys. Patients completed the Leeds Dyspepsia Questionnaire (LDQ) [24]
assessing upper gastrointestinal symptoms. Constipation severity and gut motility were evaluated
by the Rome-IV criteria [25] and the Cleveland Constipation Score (CCS) [26]. QoL and NMS
were assessed by the Non-Motor Symptoms Scale (NMSS) [27]. Physical activity was assessed by
the International Physical Activity Questionnaire (IPAQ) [28]. Clinical motor assessments were
performed by one neurologist during a patient's ‘on’ state, as an objective measure of the prevailing
motor function, in accordance with the Movement Disorder Society – Unified Parkinson’s Disease
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Rating Scale – Part III (MDS-UPDRS III) criteria [29]. Medications were compared following
standard methods for calculating daily levodopa equivalent dose (LED) [30], whilst chronic pain
severity was assessed by the Visual Analogue Scale [31].

Statistical analysis
Normal distribution of all data was confirmed using the Shapiro-Wilk test. Independent t-tests were
used to analyse differences between groups for continuous variables. Chi-squared (χ2) tests were
used to compare differences between categorical variables. Logistic and linear regression models
were constructed to evaluate differences in the prevalence of various GI symptoms between the PD
and HC groups, as well as within the PD cohort, after controlling for demographic and clinical
variables. Correlation of clinically relevant variables was evaluated using Pearson’s correlation test.
p<0.05 was considered significant. Data analysis was performed using SPSS, version 25 (SPSS Inc,
Chicago, Illinois, USA).

Results:

Demographic characteristics
103 PD patients and 81 HC’s were enrolled into the study (Table 1). 56.3% of the PD participants
were male with a mean age of 67.1years (range 35-88, standard deviation (SD) 12.2), whilst two
thirds of the HCs were female, with a mean age of 62.4 years (range 18-90, SD 15.6, p=0.001). For
the combined cohort (PD and HC), 80% of the participants were married and identified as
Caucasian. The mean Body Mass Index was 26.0 (SD 4.90) and 5.5% of subjects reported a history
of diabetes, with no statistically significant differences observed between the groups for these
measures. Biochemical analysis between the two groups showed that PD patients had lower total
cholesterol levels (4.8; SD 0.9 vs 5.2; SD 1.1, p=0.014), lower high density lipoprotein (HDL)
levels (1.4; SD 0.4 vs 1.6; SD 0.4, p=0.033), and lower albumin levels (38.7; SD 3.5 vs 39.8; SD
3.1, p=0.023), compared to the HC group, although still within normal physiological ranges.
Approximately one third of all participants identified as being prior smokers and approximately
88% reported daily caffeine consumption, although PD participants did report a lower daily intake
of 2.3 (SD 1.7) vs 3.1 (SD 1.8) cups (p=0.003). Additionally, PD patients reported a lower rate of
alcohol consumption, (70% vs 87.7%, p=0.003) (Table 1).
Within the PD cohort, the mean age of diagnosis was 58.8 years (SD 13.6) and mean duration of
disease was 9.2 years (SD 6.5), with 49.5% of patients reporting a late onset diagnosis (>60 years)
5

and 10.7% being diagnosed as young onset (<40 years) (Table 2). Approximately one third of PD
patients had either a tremor dominant or akinetic rigid phenotype. More than half identified
troublesome motor fluctuations, particularly dyskinesias, with more than 80% reporting
medications ‘wearing off’ prior to their next dose. Of the NMS, three quarters reported hyposmia,
half reported Rapid Eye Movement Sleep Behaviour Disorder and 60.2% recognised suffering from
constipation. Approximately 5% of the PD cohort was treatment naïve, 90% utilised oral levodopa,
35% dopamine agonists (DA), 18% monoamine oxidase-B inhibitors (MAO-B), 13%
anticholinergics, 23% catechol-O-methyltransferase (COMT) inhibitors and 13% amantadine. Of
those receiving device-assisted therapies, 9% utilised levodopa-carbidopa intestinal gel (LCIG)
infusions, 11% Deep Brain Stimulation (DBS) and 7% subcutaneous apomorphine infusions.

Clinical characteristics of the cohort

Gastrointestinal symptoms

Subjects with PD reported increased lower and upper gastrointestinal symptoms compared to the
HC group. Definitive functional constipation diagnosed by the Rome-IV criteria (score  2, range
0-15) confirmed 78.6% of PD participants vs 28.4% of HC suffered from constipation (χ2=46.6,
df=1, p<0.001, Table 1). The higher mean constipation score of 4.4 (SD 3.5) vs 1.1 (SD 1.4)
(p<0.001), gave an odds ratio of 9.3 (95% confidence interval 4.7-18.2) for PD patients to suffer
from constipation (Figure 1A). Furthermore, the CCS (range 0-30) confirmed increased
constipation severity in PD patients; 7.2 (SD 4.7) vs 3.1 (SD 2.9) in HCs (p<0.001) (Figure 1B).
Examination of the BSS (scale of 1-7) reflected lower scores (firmer and lumpier stools) in PD
subjects (mean score = 2.8; SD 1.5) as compared with HCs (mean score = 3.9; SD 1.3) (p<0.001)
(Figure 1C). Weak negative correlations were apparent between BSS and Rome-IV constipation
scores (r=-0.171, p=0.020) for the combined cohort, confirming individuals with increased
constipation severity tended to have firmer stools (Figure 2A). Upper GI dysfunction assessed by
the LDQ (range 0-40) also reflected increased symptom burden in the PD cohort, with subjects
reporting increased indigestion (18.4% vs 8.6%), nausea (15.6% vs 7.4%), as well as excess
fullness and bloating (20.4% vs 14.8%) (χ2=15.2, df=7, p=0.034). Moreover, the mean LDQ score
was higher in the PD (8.3; SD 7.7) compared to the HC group (4.6; SD 6.1) (p=0.001), reflecting a
higher severity of symptoms (Figure 1D).

Chronic pain, physical activity and lifestyle influences
6

Various physical and functional measures that influence GI function impacted the PD cohort more
substantially. Chronic pain (>3 months) was more frequently reported in the PD group (72.8% vs
39.5%, p<0.001), in addition to PD patients reporting a higher mean pain score (4.9; SD 2.5 vs 3.9;
SD 1.7, p=0.046), as assessed by the Visual Analogue Scale. No differences in analgesia use,
including opioids, were noted between the groups. In the combined population, linear regression
modelling showed that those with chronic pain and with higher pain severity scores were more
likely to report increased constipation severity (CCS; =-0.349, r2=0.195, p<0.001 and Rome-IV
score; =-0.334, r2=0.116, p<0.001) and increased upper GI dysfunction (LDQ score; =-0.264,
r2=0.145, p<0.001) after controlling for patient age and sex.

Physical activity assessed by the IPAQ identified that patients with PD reported a lower physical
activity score (1823.6 (metabolic-equivalent) MET-minutes/week; SD 1693.6) compared to the HC
group (2942.4 MET-minutes/week; SD 2620.9, p=0.001). Likewise, a higher proportion of PD
patients had lower IPAQ categorical scores (35.2% vs 19.8%, p=0.029), inferring a lower score
category (<600 MET-minutes/week). Similarly, PD patients reported an increased mean daily
sitting time of 6.5 (SD 3.5) hours per day, compared to the HC group 4.8 (SD 2.3) (p<0.001, Table
1). Additionally, significant correlations were also identified in the whole cohort between the IPAQ
score and the CCS (r =-0.271, p<0.001) and the IPAQ Score and the Rome-IV score (r =-0.256,
p<0.001), indicating that those patients with reduced physical activity had increased constipation
severity (Figure 2B). Caffeine intake and smoking status did not appear to impact on either upper or
lower GI symptoms or NMS in the combined or PD cohorts. However, within the combined and PD
cohorts, those who consumed any alcohol were noted to report decreased constipation severity, as
assessed by the Rome-IV criteria (=0.194, r2=0.063, p=0.008) and CCS (=0.174, r2=0.060,
p=0.018), whilst also reporting increased IPAQ scores ( =-0.188, r2=0.035, p=0.011), when
controlling for age and sex.

Logistic regression models, evaluating differences between the PD and HC groups for specific GI
complaints, showed that statistical significance persisted for differences in the CCS score (Wald
χ2=22.1, df=5, p<0.001), Rome-IV criteria (Wald χ2=25.8, df=5, p<0.001), BSS (Wald χ2=12.3,
df=5, p<0.001), LDQ score (Wald χ2=9.4, df=5, p=0.002), most troublesome upper GI symptom
assessed by the LDQ (Wald χ2=3.7, df=5, p=0.047), chronic pain (Wald χ2=6.5, df=5, p=0.011) and
the IPAQ score (Wald χ2=6.0, df=4, p=0.015) after controlling for age, sex, alcohol and caffeine
consumption and the IPAQ score.
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Parkinson’s disease cohort: clinical characteristics and influences of therapies
The PD cohort’s mean daily LED was 824.8 mg (SD 527.3), with a mean ‘on’ MDS-UPDRS III
score of 32.9 (SD 17.7), (range 0-132) (Table 2). Within the PD cohort, linear regression models
were used to assess the effect of PD duration on various GI symptoms. After controlling for age,
sex and daily LED, advancing PD duration reflected increased constipation severity (CCS; =0.239,
r2=0.129, p=0.039 and the Rome-IV criteria; =0.129, r2=0.326, p=0.048) (Figures 3, A and B).
Similarly, advancing PD duration was associated with increased upper GI symptoms, as assessed by
the LDQ, after controlling for patient age, sex and daily LED (=0.120, r2=0.124, p=0.048).

No correlations between PD phenotype or daily LED and upper and lower GI symptoms were
identified, including the BSS. However, motor fluctuations, hallmarked by dyskinesias, were more
frequently observed in patients with increased constipation severity, when controlling for patient
age, sex and daily LED (CCS; =-0.146, r2=0.106, p=0.043 and Rome-IV criteria; =-0.163,
r2=0.143, p=0.047). Motor fluctuations were also significantly more prevalent in PD patients with
increased LDQ scores, (=-0.252, r2=0.165, p=0.018), controlling for patient age, sex and daily
LED. Furthermore, clinically significant differences were noted between sexes, with PD females
reporting worse constipation severity (CCS; =0.153, r2=0.139, p=0.044 and Rome-IV criteria;
=0.142, r2=0.125, p=0.048), as well as upper GI dysfunction, particularly nausea and indigestion
(LDQ; =0.242, r2=0.167, p=0.013), controlling for patient age, PD duration and daily LED.
Analysis of NMS in the PD cohort identified an MDS NMSS Total Score of 62.7 (range 0-243, SD
42.9), with a subgroup domain 6 (gastrointestinal symptoms) score of 6.1 (range 0-26, SD 6.3),
indicating a significant negative impact to patient QoL.

When evaluating PD therapies, no significant differences reflecting either upper or lower GI
dysfunction were identified in patients who were taking levodopa, MAO-B inhibitors,
anticholinergics, COMT inhibitors or amantadine. However, patients receiving LCIG reported
increased upper GI dysfunction with higher LDQ scores, particularly excess fullness and bloating,
( =-0.163, r2=0.061, p=0.046), after controlling for patient age, sex and PD duration. PD patients
using a DA showed markedly reduced BSS after controlling for age, sex and PD duration (=0.248,
r2=0.209, p=0.008), with corresponding increases in CCS and Rome-IV constipation scores that did
not quite reach statistical significance (p=0.052).
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Discussion:
We identified clinically significant GI related differences across a number of demographic and
clinical characteristics in patients with PD (Figure 4). Both upper and lower GI dysfunction was
prevalent in PD patients, reflecting a negative impact to their clinical management and QoL.
Constipation was prevalent in the PD group, at comparable frequencies to other studies [5, 12].
However, constipation was notably underrecognised by many PD participants, with only 60% of
patients self-recognising their issue, compared to 79% meeting the diagnostic criteria, according to
Rome-IV criteria (Table 1). Increased constipation prevalence and severity in the PD cohort was
supported by two internationally validated constipation scales, the CCS and the Rome-IV criteria,
both unanimously suggesting that lower GI dysfunction, hallmarked by constipation, was more
prevalent and severe in PD patients.
The BSS rating correlated well with a patient’s constipation severity, showing PD patients to have
lower BSS overall (harder and lumpier stools), which is likely resultant of slowed colonic transit
times [32]. In addition, upper GI dysfunction was more prevalent and severe in PD patients,
particularly the symptoms of indigestion, nausea and excess fullness and bloating. These symptoms
likely result from delayed gastric emptying and gastroparesis, which may be seen in approximately
70% of PD patients [12]. However, a recent meta-analysis suggests this number may be an
overestimation and is dependent on the type of assessment utilised, either by gastric scintigraphy or
breath test studies [33]. The increased rates of motor fluctuations and dyskinesias that were seen in
patients with higher LDQ scores, imply ineffective levodopa absorption in the small intestine,
manifesting as a delayed or complete loss of benefit [12].

Chronic pain is endemic in PD, with other studies reporting a prevalence of between 40-83% [34].
Our PD cohort supports these findings, reflecting that nearly three quarters of patients, compared to
40% of HC’s, live with chronic pain. Pain is often related with a significant negative impact to a
patient’s QoL and GI function, with this study demonstrating that the presence of chronic pain was
significantly associated with both upper and lower GI dysfunction. Following on from this, chronic
pain often poses significant management difficulties due to the reinforcement of a vicious positive
feedback loop; constipation perpetuates abdominal discomfort that induces pain and provokes
worsening constipation severity. Interestingly, the criteria proposed by Ford et al., which
categorises PD related pain originating from either musculoskeletal pain, dystonia-associated pain,
9

radicular or peripheral pain, central pain, or akathisia [35], may fail to recognise the significant
associations between chronic pain and GI related causes, as suggested by our findings.
Physical activity also has significant influences on PD-related GI function. We identified that
patients with PD had lower daily physical activity scores and increased daily sitting times overall.
Importantly, we showed that a reduced level of physical activity correlated with the severity of
constipation in the combined cohort and PD group. This highlights that exercise should be
considered as an important modifiable risk factor for constipation in PD and could be considered as
a useful treatment strategy [5]. Other lifestyle factors, including caffeine intake and smoking status,
previously suggested as potential risk modifiers for PD development [36], did not appear to have
any significant effect on GI function in our study. Interestingly, alcohol consumption and increased
physical activity were consistent with a lower severity of constipation. These findings suggest that
individuals with more troublesome constipation were less likely to exercise or drink alcohol.

Blood biochemical analysis within our cohort showed subtle, yet interesting insights into potentially
important nutritional differences between PD and HC patients. Although relatively minor and still
within normal physiological range, lower total cholesterol, HDL and albumin levels in PD may
reflect an emerging pattern suggestive of malnourishment [37].

Within our PD cohort we showed that increased PD duration was significantly implicated in the
severity of constipation, with older PD patients reporting increased constipation. With increasing
PD duration patients were more likely to report increased upper and lower GI dysfunction severity,
possibly consistent with spreading α–Synuclein pathology through the ENS [38], although this is
controversial [39]. No associations between PD phenotypes and any GI symptoms were identified.
However, patients with motor fluctuations, particularly dyskinesias, were more likely to report
increased constipation and upper GI dysfunction severity. These findings suggest that motor
fluctuations may arise due to worsening gastroparesis and gastric emptying, impairing the
absorption of antiparkinsonian drugs [12, 19].

Sex differences in PD are also becoming increasingly recognised and constitute significant
implications to a patient’s QoL and their clinical management [40]. Here, PD females reported
worse constipation and upper GI dysfunction severity, particularly reflecting increased nausea and
indigestion, compared to men with PD. The mechanisms behind these findings are poorly
understood but may reflect women’s moderately increased PD duration (11 vs 7 years), although
younger age (55 vs 61 years), respectively. Other possibilities include potentially increased
10

sensitivity from PD medications, such as levodopa, in addition to poorly understood oestrogenic
effects in the gut and central nervous system, [40] or reporting bias.

PD treatment appears to reflect significant implications to both upper and lower GI function, as well
as patient QoL. LCIG use was associated with an increased severity of excess fullness and bloating
compared to other therapies. Perhaps not surprisingly, a percutaneous infusion of levodopacarbidopa through a gastrojejunostomy tube to the upper GI tract may account for some of the
mechanical and pharmacological implications responsible for increased bloating and excess fullness
[41]. Furthermore, patients utilising a DA showed a lower BSS, suggesting an increased risk for
constipation. No significant differences between upper or lower GI dysfunction were found in
patients taking levodopa, MAO-B inhibitors, COMT inhibitors, amantadine and anticholinergics.
Although greater constipation severity was noted in patients using anticholinergics, despite not
reaching statistical significance, likely due to the smaller population size. The treatment related
effects identified from patients utilising LCIG suggested increased rates of upper GI dysfunction.
However, it is unclear whether such therapy effects are genuine or indicative of increased PD
severity, rather than PD duration, as was discounted by our analysis.

Whilst our data does not address certain potential confounding factors, including other
comorbidities and medication effects, several important GI related differences in PD were
identified. Medication use for GI dysfunction (e.g., laxatives, anti-diarrhoea medication and reflux
medication), as well as GI tract medical diagnosis (e.g., Inflammatory Bowel Disease,
Inflammatory Bowel Syndrome and Coeliac Disease), are important modulators in the GI measures,
but were not available and were not considered in the analysis. A relatively small sample size for
both cohorts, in addition to non-optimally matched PD and HC groups for age and sex, due to
spousal recruitment, may have resulted in a potential under-representation of GI dysfunctions from
within the HC group. It is known that constipation increases with age [42] and this may further
explain why the on average 4.7 year age difference for the PD cohort reported increased
constipation severity compared to the HC group. Our PD cohort comprised of many later-stage
patients, with a mean disease duration of 9.2 years (SD 6.5). Consequently, the reported prevalence
of GI NMS in our study may not represent the general PD population. Interestingly, our HC group
reported a constipation frequency of 28.4%, which is slightly higher than other worldwide estimates
that vary between 12-19% [42]. However, this frequency of constipation was comparable to other
studies from Sydney, Australia, [43] and may reflect differences in cultural backgrounds and dietary
patterns, particularly fibre content. [44] Furthermore, the definition of constipation in Parkinson’s
disease is inconsistent and highly dependent on the questionnaire used, with more than 10 different
11

definitions of constipation throughout the Parkinson’s disease literature. [14] Although our
definition of constipation was derived from the Rome-IV criteria, the resulting constipation
prevalence of 78% in the PD cohort would be unlikely to be supported by the CSS criteria, with our
mean PD cohort value of 7.2, as some studies have employed a cut-off score as high as 15 to define
constipation. [26] Accordingly, the type of questionnaire utilised to define constipation is defining.

The findings of this study should be interpreted in light of its limitations, including the selfreporting nature of the data and potential selection bias of the study population being drawn from
specialist PD clinics. The greater GI dysfunction burden demonstrated by PD patients in this study
may be a reflection of recruitment bias inherent in this cross-sectional survey design, whereby PD
patients with greater GI symptomology may have been over-represented among the clinic attendees.
Furthermore, our sample only reflected the experience of patients from a single metropolitan area,
whereas previous studies from Australia have shown PD patients from regional areas to be
comparably older with an older age of diagnosis [45].

Conclusion:

We highlight novel clinical associations and unravel their influences on GI dysfunction in PD, a
NMS that is hallmarked by prevalent constipation and upper GI dysfunction in patients with PD.
Increasing PD duration, motor fluctuations, chronic pain, decreased physical activity, female
gender, as well as certain PD therapies, appear to predispose PD patients and negatively impact GI
dysfunction. In light of our findings, we recommend optimising and proactively treating
constipation and upper GI symptoms, encouraging physical exercise, treating chronic pain as well
as rationalising PD therapies. These practical measures aim to modify risk factors and may help to
reduce the considerable burden of GI dysfunction in PD.
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Figures:
Figure 1: Plots Identifying Gastrointestinal Dysfunction in Parkinson’s Disease and Healthy
Control Subjects.

A) Rome IV Criteria Constipation Score comparison suggested increased constipation severity in
the Parkinson’s disease cohort; 4.4 (SD 3.5) compared to the healthy control group; 1.1 (SD 1.4)
(p<0.001).

B) Cleveland Constipation Score comparison suggested increased constipation severity in
Parkinson’s disease patients compared to healthy controls; 7.2 (SD 4.7) vs 3.1 (SD 2.9)
(p<0.001).
C) Bristol Stool Scale comparison identified lower scores in Parkinson’s disease subjects (firmer
and lumpier stools); 2.8 (SD 1.5) compared to the healthy control group; 3.9 (SD 1.3)
(p<0.001).
D) Leeds Dyspepsia Questionnaire score comparison showed higher scores in the Parkinson’s
disease cohort; 8.3 (SD 7.7) compared to the healthy control group; 4.6 (SD 6.1) (p=0.001),
suggesting increased upper gastrointestinal symptom severity.
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Figure 2: Correlations Identifying Gastrointestinal Dysfunction in Parkinson’s Disease.

A) Weak negative correlations between the Bristol Stool Scale and Rome-IV Criteria Constipation
score were identified for the combined cohort, (r=-0.171, p=0.020), confirming individuals with
increased constipation severity tended to have firmer stools.

B) Correlations within the combined cohort between the International Physical Activity
Questionnaire score and the Cleveland Constipation Score (r =-0.271, p<0.001), and the
International Physical Activity Questionnaire score and the Rome-IV Criteria Constipation
score (r =-0.256, p<0.001), indicated that patients with reduced physical activity experienced
increased constipation severity.

Figure 3: Correlations Between Parkinson’s Disease Duration and Constipation Severity Scores.
A) Correlation showing that increasing Parkinson’s disease duration reflected increased
constipation severity, according to the Cleveland Constipation Score.
B) Correlation showing that increasing Parkinson’s disease duration reflected increased
constipation severity, according to the Rome IV Criteria Constipation scores.

Figure 4: Factors Leading to Gastrointestinal Dysfunction in Parkinson’s Disease.
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Tables:
Table 1: Cohort Demographic and Clinical Characteristics

Number of Patients (n=)
Age, (years) [SD, Range]
Gender, (%)
Male
Female
Marital Status, (%)
Married / de facto
Single
Widowed
Other
Ethnicity, (%)
Caucasian
Asian
Middle Eastern
Other
Body Mass Index, [SD]
Smoking History, (%)
Current Smoker
Prior Smoker
Pack Year History, [SD]
Alcohol Consumption, (%)
< Weekly
Several Times Weekly
Daily
Caffeine Consumption (Coffee/Tea),
(%)
Number of Daily Cups, [SD]
History of Diabetes, (%)
Gastrointestinal Symptoms
Cleveland Constipation Score, [SD]
Constipation Score as per Rome IV
Criteria, [SD]
Functional Constipation as per
Rome IV Criteria, (%)
Bristol Stool Score, [SD]
Leeds Dyspepsia Questionnaire (LDQ)
Score, [SD]
Most Troublesome Symptom, (%)
Indigestion
Heartburn
Regurgitation
Belching
Nausea

Parkinson’s
Disease
103
67.1 [12.2,
33-88]
56.3
43.7

Healthy
Control
81
62.4 [15.6,
18-90]
32.1
67.9

Test
Statistic

p
value

t=2.3 (182)^

0.023

χ2=10.7 (1)∞

0.001

χ2=4.2 (3)∞

0.244

χ2=2.3 (3)∞

0.506

76.7
9.7
5.8
7.7

85.1
9.9
1.2
3.7

78.6
3.9
6.8
10.7
25.7 [5.2]

79.0
6.2
2.5
12.3
26.2 [4.6]

t=-0.7 (182)^

0.485

1.9
36.9
13.3 [13.8]
70.0
23.5
31.1
16.7
85.4

3.7
33.7
14.4 [14.6]
87.7
27.2
33.3
28.4
91.4

χ2=0.6 (1)∞
χ2=0.2 (1)∞
t=-0.3 (63)^
χ2=8.7 (1)∞
χ2=0.3 (1)∞
χ2=0.8 (1)∞
χ2=3.6 (1)∞
χ2=1.5 (1)∞

0.457
0.659
0.758
0.003
0.574
0.778
0.057
0.219

2.3 [1.7]
4.9

3.1 [1.8]
6.2

t=3.0 (182)^
χ2=0.2 (1)∞

0.003
0.695

7.2 [4.7]
4.4 [3.5]

3.1 [2.9]
1.1 [1.4]

t=6.9 (182)^
t=7.9 (182)^

<0.001
<0.001

78.6

28.4

χ2=46.6 (1)∞

<0.001

2.8 [1.5]
8.3 [7.7]

3.9 [1.3]
4.6 [6.1]

t=4.0 (182)^
t=3.5 (182)^

<0.001
0.001

χ2=15.2 (7)^

0.034

18.4
7.8
6.8
7.8
15.6

8.6
9.9
7.4
6.2
7.4

Vomiting
Excess Fullness / Bloating
None
Chronic Pain Over Last 3 Months, (%)
Pain Score (Visual Analogue Scale),
[SD]
International Physical Activity
Questionnaire (IPAQ) Score (METminutes/week), [SD]
IPAQ Categorical Score, (%)
Low
Moderate
High
Sitting Hours / Day, [SD]
Able to Walk 1km, (%)
Able to Climb 1 Flight of Stairs,
(%)
Biochemical Characteristics, [SD]
Erythrocyte Sedimentation Rate
C-Reactive Protein
Total Cholesterol
Low Density Lipoprotein
High Density Lipoprotein
Triglycerides
Random Glucose
HbA1c%
Albumin

1
20.4
22.3
72.8
4.9 [2.5]

0
14.8
45.7
39.5
3.9 [1.7]

1823.6
[1693.6]

2942.4
[2620.9]

χ2=20.7 (1)∞
t=2.0 (105)^

<0.001
0.046

t=-3.5 (182)^

0.001

χ2=7.1 (2)∞

0.029

35.2
37.9
26.2
6.5 [3.5]
73.8

19.8
39.6
40.7
4.8 [2.3]
97.5

t=3.7 (182)^
χ2=19.3 (1)∞

<0.001
<0.001

86.4

100

χ2=11.9 (1)∞

0.001

9.5 [13.4]
3.9 [10.8]
4.8 [0.9]
2.7 [0.7]
1.4 [0.4]
1.3 [1.0]
5.8 [0.6]
5.3 [0.4]
38.7 [3.5]

9.5 [10.4]
2.2 [2.5]
5.2 [1.1]
2.9 [0.9]
1.6 [0.4]
1.5 [0.9]
5.9 [0.9]
6.0 [5.2]
39.8 [3.1]

t=-0.1 (181)^
t=1.4 (182)^
t=-2.5 (182)^
t=-1.5 (178)^
t=-2.2 (181)^
t=-1.2 (182)^
t=-0.8 (182)^
t=-1.2 (182)^
t=-2.3 (182)^

0.991
0.177
0.014
0.132
0.033
0.239
0.438
0.217
0.023

^(Independent Sample t-Test); ∞(Pearson’s chi-squared test); df (degrees of freedom), SD [Standard
Deviation]

Table 2: Parkinson’s Disease Clinical Characteristics
Age at Diagnosis, (years) [SD, Range]
Parkinson’s Disease Duration, (years) [SD, Range]
Parkinson’s Disease Phenotype, (%)
Tremor Dominant
Postural Instability and Gait Impairment
Akinetic Rigid
Young Onset (<40 years)
Late Onset (>60 years)
Genetic Diagnosis, (%)
Disease Complications, (%)
Motor Fluctuations
Dyskinesia
Wearing off
Impulse Control Disorder
Non-motor Symptoms, (%)
Hyposmia
REM Sleep Behaviour Disorder
Constipation
MDS Total Non-Motor Symptoms Score (NMSS), [SD]
NMSS – Domain 6 (Gastrointestinal Symptoms), [SD]
Levodopa Equivalent Daily Dose (mg), [SD, Range]
MDS Unified Parkinson’s Disease Rating Scale-III (‘on’ state), [SD,
Range]
Parkinson’s Disease Therapy, (%)
Treatment Naïve
Oral Levodopa
Dopamine Agonist
Monoamine Oxidase B Inhibitor
Anticholinergic
Catechol-O-methyl Transferase Inhibitor
Amantadine
Levodopa-Carbidopa Intestinal Gel (LCIG)
Deep Brain Stimulation
Apomorphine (Subcutaneous Infusion)
SD [Standard Deviation]

58.8 [13.6, 24-88]
9.2 [6.5, 1-30]
30.1
20.4
38.9
10.7
49.5
1.9
58.3
58.3
81.6
19.4
73.8
48.5
60.2
62.7 [42.9]
6.1 [6.3]
834.8 [527.3, 0-2186]
32.9 [17.7, 5-91]

(n=5) 4.9
(n=92) 89.3
(n=36) 35.0
(n=19) 18.4
(n=13) 12.6
(n=24) 23.3
(n=13) 12.6
(n=9) 8.7
(n=11) 10.7
(n=7) 6.8

